Physician profile
Heather L Gitchell
NPI 1487680120
$7,904.22
in general payments reported to CMS, 2019-2025
31 companies · $2,356 in 2025
The $2,356 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $131 · 2021: $1,417 · 2022: $1,052 · 2023: $1,193 · 2024: $1,032 · 2025: $2,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,564 · Consulting Fee: $1,000 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,563.85 |
| Consulting Fee | $1,000.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,098.10 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $1,792.72 | 2021-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Abbvie INC. | $727.04 | 2022-2025 | |
| Sight Sciences, INC. | $620.59 | 2020-2025 | Omni Surgical System, Tearcare System |
| Mallinckrodt Hospital Products INC. | $363.69 | 2023-2025 | Acthar |
| Rxsight INC | $272.23 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $254.16 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $225.04 | 2019-2023 | Eylea |
| Shire North American Group INC | $196.73 | 2019 | |
| Allergan, INC. | $162.59 | 2019-2022 | |
| Glaukos Corporation | $151.19 | 2021 | |
| Maculogix, INC. | $134.17 | 2019 | |
| Thea Pharma INC. | $106.88 | 2022-2025 | Iyuzeh |
| Dompe US, INC. | $96.92 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $85.28 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $78.77 | 2021-2023 | |
| Biotissue Holdings INC. | $69.48 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $68.12 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $46.66 | 2021 | |
| Apellis Pharmaceuticals, INC. | $45.32 | 2023-2024 | Syfovre |
| Aerie Pharmaceuticals, INC. | $44.66 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $41.85 | 2024 | Tecnis Iol, Tecnis Simplicity |
| Oyster Point Pharma, INC. | $36.87 | 2022-2023 | Tyrvaya |
| Ivantis, INC | $30.20 | 2021 | |
| Rayner Intraocular Lenses Limited | $26.22 | 2025 | Rayone Aspheric, Rayone Spheric, Rayner Cataract Set 1 |
| Kala Pharmaceuticals, INC. | $24.32 | 2021 | |
| Harrow Eye, LLC | $22.79 | 2025 | Iheezo |
| Astellas Pharma US INC | $22.23 | 2023 | |
| Abb Con-Cise Optical Group LLC | $20.52 | 2019 | |
| Katena Products, INC. (Dba Corza Medical) | $19.72 | 2019 | |
| Horizon Therapeutics Plc | $19.16 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Gitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.